Comparative Antidiabetic, Hypolipidemic, and Antioxidant Properties of *Phyllanthus niruri* in Normal and Diabetic Rats

Jasmin H. Bavarva and A.V.R.L. Narasimhacharya

Department of Biosciences, Sardar Patel University, Gujarat, India

Abstract

The antidiabetic, hypolipidemic, and antioxidant properties of *Phyllanthus niruri* (L) (Euphorbiaceae) were compared in normal, insulin-dependent diabetes mellitus (IDDM), and non–insulin-dependent diabetes mellitus (NIDDM) animals through evaluating the effects on carbohydrate and lipid metabolism and antioxidant activities. The alcohol extract of *Phyllanthus niruri* produced significant antidiabetic effect in IDDM alone but lowered lipid profiles and improved body antioxidant activities in both IDDM and NIDDM animals. This investigation revealed that the lipid-lowering effect of *Phyllanthus niruri* is independent from its antidiabetic action.

Keywords: Antidiabetic, hypolipidemic, IDDM, NIDDM, *Phyllanthus niruri*.

Introduction

Diabetes mellitus (DM) is one of the major health problems affecting a significant portion of the population worldwide (Zimmet et al., 2001). DM is classified as insulin-dependent diabetes mellitus (IDDM) and non–insulin-dependent diabetes mellitus (NIDDM). Both IDDM and NIDDM share most common symptoms such as long-term hyperglycemia leading to macrovascular and microvascular complications (Attele et al., 2002). It has been established that hyperglycemia is the principal cause of diabetic complications (Brownlee 2001). Although glucose levels are controlled by medication, atherosclerosis can still develop in diabetic patients (Steinberg et al., 2000), which is a potent independent risk factor for cardiovascular disease (CVD) (American Diabetes Association, 1998). People with diabetes exhibit a pattern of dyslipidemia characterized by elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C) (Resnick et al., 2002). In addition, diabetic conditions increase oxidative stress (Glugliano et al., 1996) and deplete antioxidant levels in the body (Fonseca et al., 2004). Therefore, improvement in glucose, lipid, and antioxidant profiles could be useful in management of diabetes and its complications.

*Phyllanthus niruri* L. (Euphorbiaceae) (syn. *Phyllanthus amarus* Schum & Thonn) is a traditionally well-known plant in India for its Ayurvedic and folklore medicinal uses such as in the treatment of jaundice (Raja Reddy, 1988), hepatitis, dysentery, and irritating sores (Reddy et al., 1993). The aqueous and methanol extracts of the leaves of this plant were reported to be hypoglycemic (Ramakrishnan et al., 1982; Raphael et al., 2002), hypotensive and hypoglycemic in human hypertensive (and secondarily diabetic) subjects but was found to be neither hypercholesterolemic nor hypocholesterolemic (Srividya & Periwal, 1995). However, Khanna et al. (2002) reported that *Phyllanthus niruri* lowers the serum lipid levels in hyperlipemic rats and the antioxidant activity of this plant has been demonstrated *in vitro* (Raphael et al., 2002). These reports, however, pertain to alloxan-induced diabetic animals, hypertensive human subjects, hyperlipemic animals, and *in vitro* observations. Besides, the aqueous extracts of *P. amarus* were shown to enhance the clearance of oral glucose load though they did not...
lower fasting blood glucose (FBG) in normal albino rabbits (Moshi et al., 1997) but were ineffective in lowering either FBG or postprandial blood glucose levels in NIDDM subjects (Moshi et al., 2001). As no reports are available with reference to comparative studies on the effect(s) of *Phyllanthus niruri* on carbohydrate, lipid metabolism, and antioxidant activity in IDDM and NIDDM subjects, a comparative evaluation of antidiabetic, hypolipidemic, and antioxidant properties of *Phyllanthus niruri* in normal, IDDM, and NIDDM animals was undertaken.

**Materials and Methods**

**Collection and extract preparation**

The young leaves of the plant *Phyllanthus niruri* L. were collected from the university’s botanical garden and authenticated by Dr. A.S. Reddy, Department of Biosciences, Sardar Patel University (voucher specimen no. JHB-01). Shade-dried leaves were powdered and extracted with 95% ethanol. The extract (PnlE) was filtered, dried at room temperature (yield 13.3% w/w), and the residue was stored at 4°C for later use.

**Animals**

Male Charles Foster rats were used for the current study. Animals were housed in polypropylene cages and maintained under ambient room temperature. They were fed standard pellet diet (Pranav Agro Ltd., Pune, India) and water *ad libitum*. The institutional animal ethics committee approved the study.

**Induction of diabetes**

*Insulin-dependent diabetes mellitus*

Rats weighing 200–250 g were fasted overnight and then given a single intraperitoneal (i.p.) injection of alloxan monohydrate (120 mg/kg b.w., Loba Chemie, Mumbai, India) dissolved in normal saline. Induction of diabetic condition was confirmed by FBG estimation (>140 mg/dL) over a period of 2 weeks.

*Non-insulin-dependent diabetes mellitus*

The model was developed according to the description of Bonner-Weir et al. (1981). Males aged 48 ± 2 h were injected (i.p.) with streptozotocin (Sisco Research Laboratories, Mumbai, India) in citrate buffer (pH 4.5) at a dose of 100 mg/kg b.w. The animals showing FBG levels >140 mg/dL after 12 weeks were considered as diabetic animals.

**Experimental procedure**

For the experiment, 48 rats were used (16 normal, 16 IDDM, and 16 NIDDM). Six groups of eight animals each were divided as follows. Group I: normal, vehicle-administered animals; group II: normal, PnlE-administered animals; group III: IDDM, vehicle-administered animals; group IV: IDDM, PnlE-administered animals; group V: NIDDM, vehicle-administered animals; and group VI: NIDDM, PnlE-administered animals.

Treatment was given at a dose of 300 mg/kg b.w. per day in 1 mL of 2% (v/v) Tween 80 suspension for 4 weeks by oral route. Control animals received equal volume of vehicle (1 mL of 2% Tween 80) only. At the end of the experimental period, the animals were deprived of food overnight and sacrificed under mild anesthesia; blood and liver tissues were collected and analyzed immediately.

**Oral glucose tolerance test**

Two days before the termination of the experiment, the oral glucose tolerance test (OGTT) was performed to assess the sensitivity to high glucose load. For this purpose, overnight-fasted rats were fed orally 2 g glucose/kg b.w. Blood was collected at 0-, 60-, and 120-min intervals from orbital sinus for glucose estimation.

**Analytical methods**

Plasma glucose levels were measured by the o-toluidine method (Webster et al., 1971), hepatic glycogen was extracted with 30% KOH, and the yield was determined by anthrone-sulfuric acid method (Seifter et al., 1950). Plasma cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were estimated by ferric perchlorate-sulfuric acid and glycerol-3-phosphate: O₂ 2-oxidoreductase (GPO) methods, respectively (Wybenga et al., 1970; McGown et al., 1983). Low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), and atherogenic index (AI) were calculated (Friedwald et al., 1972). The hepatic hexokinase (EC 2.7.1.1) was determined following the methods prescribed by Brandstup et al. (1957). The hepatic lipids were extracted (Folch et al., 1957) and used for the estimation of total cholesterol and triglyceride content (Wybenga et al., 1970; McGown et al., 1983). The peroxidation product, thiobarbituric acid reactive substances (TBARS), was determined by the method of Niehaus & Samuelsson (1968). Activities of antioxidant enzymes superoxide dismutase (EC 1.15.1.1) and catalase (EC 1.11.1.6) were estimated according to the methods described by Kakkar et al. (1984) and Aebi (1974), respectively.
Statistical analysis

Data are presented as mean ± SEM. One-way analysis of variance (ANOVA) with Tukey’s significant difference post hoc test was used to compare differences among groups. Data were statistically handled by SPSS statistical software, version 10. p values < 0.05 were considered as statistically significant.

Results

Both IDDM and NIDDM control animals registered significantly higher plasma glucose levels (p < 0.001). A significant reduction in plasma glucose level was noted only in PnlE-administered IDDM animals (p < 0.001). However, both IDDM and NIDDM animals registered significant reduction in TC, TG, LDL-C, VLDL-C, and AI and increases in HDL-C levels with PnlE administration when compared with vehicle-administered control groups (Tables 1 and 2).

The hepatic glycogen content of IDDM and NIDDM control animals declined significantly (p < 0.001). The IDDM animals alone registered a significant rise in hepatic glycogen level (p < 0.001) with PnlE administration although both NIDDM and normal groups revealed a small increase in hepatic glycogen content upon PnlE administration. The PnlE treatment to IDDM and NIDDM animals caused a significant decline in hepatic TC and TG levels (Tables 1 and 2).

Both IDDM and NIDDM controls registered significant decline in hexokinase activity (p < 0.001; p < 0.01). The hexokinase activity increased significantly in the PnlE-administered IDDM group alone (p < 0.001) (Tables 1 and 2).

The PnlE treatment to IDDM and NIDDM animals decreased TBARS significantly (p < 0.01, p < 0.05, respectively) and caused a significant increase in catalase activity (p < 0.01, p < 0.05, respectively). However, SOD activity remained more or less unaltered in these groups (Tables 1 and 2).

A marked reduction in plasma glucose level occurred in the PnlE-treated IDDM group at 120 min compared with its counterpart. However, no improvements were found in NIDDM and normal animals (Fig. 1).

Discussion

In the current study, a significant increase in fasting blood glucose and decreases in hepatic glycogen levels and hexokinase activity was found in both untreated IDDM and NIDDM animals. PnlE administration caused a significant reduction in plasma glucose levels, increased hepatic glycogen content, and heightened the hepatic hexokinase activity in IDDM animals alone. Further, these animals also exhibited a marked improvement in glucose tolerance. The pronounced hypoglycemic effect of PnlE in IDDM animals could be due to either its insulin-like activity or its stimulatory effect on insulin. On the other hand, the lack of hypoglycemic activity of PnlE in NIDDM animals could be due to its inability to decrease the insulin resistance in these animals (Kergoat & Portha, 1985; Santosh et al., 2003). This lack of hypoglycemic activity of PnlE in NIDDM animals is reflected in their poor glucose tolerance.

Table 1. Effect of PnlE on various biochemical parameters in IDDM rats.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Normal control</th>
<th>Normal PnlE-treated</th>
<th>IDDM control</th>
<th>IDDM PnlE-treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose(^a)</td>
<td>103.73 ± 4.68</td>
<td>99.41 ± 5.02(^a)</td>
<td>217.50 ± 16.94(^a)</td>
<td>147.49 ± 5.20(^a)</td>
</tr>
<tr>
<td>Hepatic glycogen(^b)</td>
<td>21.31 ± 0.78</td>
<td>22.42 ± 0.79(^b)</td>
<td>6.11 ± 0.37(^b)</td>
<td>12.73 ± 0.52(^b)</td>
</tr>
<tr>
<td>Hepatic hexokinase(^c)</td>
<td>7.87 ± 0.24</td>
<td>7.82 ± 0.30(^c)</td>
<td>4.22 ± 0.24(^c)</td>
<td>5.91 ± 0.38(^c)</td>
</tr>
<tr>
<td>TC(^d)</td>
<td>109.95 ± 3.25</td>
<td>114.50 ± 4.06(^d)</td>
<td>153.81 ± 4.82(^d)</td>
<td>114.12 ± 3.35(^d)</td>
</tr>
<tr>
<td>TG(^e)</td>
<td>88.40 ± 4.48</td>
<td>93.53 ± 4.56(^e)</td>
<td>159.34 ± 6.22(^e)</td>
<td>124.96 ± 5.77(^e)</td>
</tr>
<tr>
<td>LDL-C(^f)</td>
<td>24.97 ± 3.96</td>
<td>22.58 ± 6.33(^f)</td>
<td>87.35 ± 4.88(^f)</td>
<td>35.22 ± 5.01(^f)</td>
</tr>
<tr>
<td>VLDL-C(^f)</td>
<td>17.67 ± 2.53</td>
<td>18.70 ± 2.58(^f)</td>
<td>31.86 ± 3.51(^f)</td>
<td>24.98 ± 3.26(^f)</td>
</tr>
<tr>
<td>HDL-C(^f)</td>
<td>67.30 ± 2.20</td>
<td>73.22 ± 6.32(^f)</td>
<td>34.59 ± 1.20(^f)</td>
<td>35.90 ± 3.30(^f)</td>
</tr>
<tr>
<td>AI(^g)</td>
<td>1.64 ± 0.02</td>
<td>1.64 ± 0.16(^g)</td>
<td>4.47 ± 0.54(^g)</td>
<td>2.16 ± 0.39(^g)</td>
</tr>
<tr>
<td>Hepatic TC(^h)</td>
<td>5.78 ± 0.22</td>
<td>4.76 ± 0.47(^h)</td>
<td>6.64 ± 0.17(^h)</td>
<td>5.53 ± 0.10(^h)</td>
</tr>
<tr>
<td>Hepatic TG(^h)</td>
<td>10.93 ± 0.45</td>
<td>10.77 ± 0.17(^h)</td>
<td>12.31 ± 0.14(^h)</td>
<td>10.60 ± 0.31(^h)</td>
</tr>
<tr>
<td>TBARS(^i)</td>
<td>0.757 ± 0.05</td>
<td>0.754 ± 0.03(^i)</td>
<td>0.939 ± 0.06(^i)</td>
<td>0.622 ± 0.03(^i)</td>
</tr>
<tr>
<td>SOD(^j)</td>
<td>3.45 ± 0.14</td>
<td>3.45 ± 0.16(^j)</td>
<td>3.15 ± 0.10(^j)</td>
<td>3.47 ± 0.14(^j)</td>
</tr>
<tr>
<td>Catalase(^k)</td>
<td>65.28 ± 4.47</td>
<td>68.47 ± 6.81(^k)</td>
<td>33.73 ± 4.29(^k)</td>
<td>58.12 ± 2.93(^k)</td>
</tr>
</tbody>
</table>

Values are mean ± SEM of eight rats. *p < 0.05, **p < 0.01, ***p < 0.001, NS (non-significant).

PnlE-treated group was compared with respective vehicle-treated group. IDDM control was compared with normal control. Values in parenthesis represent the percent change.

Units: \(^a\)mg/dL; \(^b\)mg/g; \(^c\)U/mg protein; \(^d\)mM/100 g; \(^e\)nM H\(_2\)O\(_2\) decomposed/s per g tissue.
Both IDDM and NIDDM control animals exhibited marked increases in plasma and hepatic lipid profiles along with decreased HDL-C levels. Diabetes is associated with increased plasma and tissue cholesterol and triglyceride levels with lowered HDL-C profile (Glasgow et al., 1981; Goodman et al., 1982; Kudchodkar et al., 1988). Currently, PnlE administration to both IDDM and NIDDM animals registered increased plasma and tissue cholesterol and triglyceride levels with lowered HDL-C profile (Glasgow et al., 1981; Goodman et al., 1982; Kudchodkar et al., 1988). Currently, PnlE administration to both IDDM and NIDDM animals registered decreased the level of TBARS in these groups. SOD and catalase are known to be important antioxidant enzymes that catalyze superoxide radicals and reduce peroxides, respectively (Eriksson & Borg, 1991). Although the induction of diabetes significantly reduced the hepatic catalase activity in both diabetic groups, a significant decrease in atherogenic index. Thus, while the lipid-lowering activity of PnlE appeared to be common to both IDDM and NIDDM animals, the hypoglycemic activity of PnlE is restricted to the IDDM animals alone even with a 4-week administration of PnlE (300 mg/kg b. w. per day). In this context, it is pertinent to note here that a 1-week treatment with P. amarus extract (12.5 g dose) could not lower both FBG and postprandial blood glucose in NIDDM patients (Moshi et al., 2001) although a similar dose of extract (0.1 and 1.0 g/kg b. w.) could enhance the clearance rate of oral glucose load from blood without significantly affecting FBG levels in rabbits (Moshi et al., 1997). The stem bark extract of a related species of the genus Phyllanthus (i.e., P. sellowianus), however, was found to significantly reduce the blood glucose level in streptozotocin-induced diabetic (IDDM) mice at a dose of 200 mg/kg b. w. (Hnatsyzyn et al., 2002). It is therefore evident that P. niruri (P. amarus) is ineffective in NIDDM with reference to maintenance of plasma glucose levels.

### Table 2. Effect of PnlE on various biochemical parameters in NIDDM rats.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Normal control</th>
<th>Normal PnlE-treated</th>
<th>NIDDM control</th>
<th>NIDDM PnlE-treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose</td>
<td>103.73 ± 4.68</td>
<td>99.41 ± 5.02&lt;sup&gt;NS&lt;/sup&gt; (−4)</td>
<td>200.66 ± 6.29&lt;sup&gt;***&lt;/sup&gt; (+93)</td>
<td>168.58 ± 11.32&lt;sup&gt;NS&lt;/sup&gt; (−16)</td>
</tr>
<tr>
<td>Hepatic glycogen&lt;sup&gt;+&lt;/sup&gt;</td>
<td>21.31 ± 0.78</td>
<td>22.42 ± 0.79&lt;sup&gt;NS&lt;/sup&gt; (−5)</td>
<td>8.62 ± 0.22&lt;sup&gt;***&lt;/sup&gt; (−60)</td>
<td>9.74 ± 0.41&lt;sup&gt;NS&lt;/sup&gt; (−13)</td>
</tr>
<tr>
<td>Hepatic hexokinase&lt;sup&gt;−&lt;/sup&gt;</td>
<td>7.87 ± 0.24</td>
<td>7.82 ± 0.30&lt;sup&gt;NS&lt;/sup&gt; (−1)</td>
<td>6.37 ± 0.14&lt;sup&gt;−&lt;/sup&gt; (−19)</td>
<td>6.81 ± 0.18&lt;sup&gt;−&lt;/sup&gt; (−10)</td>
</tr>
<tr>
<td>TC&lt;sup&gt;+&lt;/sup&gt;</td>
<td>109.95 ± 3.25</td>
<td>114.50 ± 4.06&lt;sup&gt;NS&lt;/sup&gt; (−4)</td>
<td>150.76 ± 1.58&lt;sup&gt;***&lt;/sup&gt; (+37)</td>
<td>131.19 ± 2.66&lt;sup&gt;−&lt;/sup&gt; (−13)</td>
</tr>
<tr>
<td>TG&lt;sup&gt;−&lt;/sup&gt;</td>
<td>88.40 ± 4.48</td>
<td>93.53 ± 4.56&lt;sup&gt;NS&lt;/sup&gt; (−6)</td>
<td>156.62 ± 3.94&lt;sup&gt;***&lt;/sup&gt; (+77)</td>
<td>126.41 ± 6.13&lt;sup&gt;**&lt;/sup&gt; (−19)</td>
</tr>
<tr>
<td>LDL-C&lt;sup&gt;−&lt;/sup&gt;</td>
<td>24.97 ± 3.96</td>
<td>22.58 ± 6.33&lt;sup&gt;NS&lt;/sup&gt; (−10)</td>
<td>75.71 ± 1.99&lt;sup&gt;***&lt;/sup&gt; (+203)</td>
<td>54.53 ± 2.30&lt;sup&gt;−&lt;/sup&gt; (−28)</td>
</tr>
<tr>
<td>VLDL-C&lt;sup&gt;−&lt;/sup&gt;</td>
<td>17.67 ± 2.53</td>
<td>18.70 ± 2.58&lt;sup&gt;NS&lt;/sup&gt; (−6)</td>
<td>31.31 ± 2.23&lt;sup&gt;***&lt;/sup&gt; (+77)</td>
<td>25.28 ± 3.47&lt;sup&gt;−&lt;/sup&gt; (−19)</td>
</tr>
<tr>
<td>HDL-C&lt;sup&gt;−&lt;/sup&gt;</td>
<td>67.30 ± 2.20</td>
<td>73.22 ± 6.32&lt;sup&gt;NS&lt;/sup&gt; (−9)</td>
<td>36.72 ± 0.50&lt;sup&gt;−&lt;/sup&gt; (−45)</td>
<td>51.53 ± 1.12&lt;sup&gt;−&lt;/sup&gt; (−40)</td>
</tr>
<tr>
<td>AI&lt;sup&gt;−&lt;/sup&gt;</td>
<td>1.64 ± 0.02</td>
<td>1.64 ± 0.16&lt;sup&gt;−&lt;/sup&gt; (0)</td>
<td>3.34 ± 0.25&lt;sup&gt;−&lt;/sup&gt; (104)</td>
<td>2.62 ± 0.15&lt;sup&gt;−&lt;/sup&gt; (−22)</td>
</tr>
<tr>
<td>Hepatic TC&lt;sup&gt;−&lt;/sup&gt;</td>
<td>5.78 ± 0.22</td>
<td>4.76 ± 0.47&lt;sup&gt;NS&lt;/sup&gt; (−18)</td>
<td>6.57 ± 0.10&lt;sup&gt;−&lt;/sup&gt; (−14)</td>
<td>5.22 ± 0.16&lt;sup&gt;−&lt;/sup&gt; (−21)</td>
</tr>
<tr>
<td>Hepatic TG&lt;sup&gt;−&lt;/sup&gt;</td>
<td>10.93 ± 0.45</td>
<td>10.77 ± 0.17&lt;sup&gt;NS&lt;/sup&gt; (−1)</td>
<td>13.13 ± 0.18&lt;sup&gt;−&lt;/sup&gt; (−20)</td>
<td>11.87 ± 0.12&lt;sup&gt;−&lt;/sup&gt; (−10)</td>
</tr>
<tr>
<td>TBARS&lt;sup&gt;−&lt;/sup&gt;</td>
<td>0.757 ± 0.05</td>
<td>0.754 ± 0.03&lt;sup&gt;NS&lt;/sup&gt; (0)</td>
<td>0.939 ± 0.06&lt;sup&gt;−&lt;/sup&gt; (−24)</td>
<td>0.699 ± 0.05&lt;sup&gt;−&lt;/sup&gt; (−26)</td>
</tr>
<tr>
<td>SOD&lt;sup&gt;−&lt;/sup&gt;</td>
<td>3.45 ± 0.14</td>
<td>3.45 ± 0.16&lt;sup&gt;−&lt;/sup&gt; (0)</td>
<td>3.23 ± 0.10&lt;sup&gt;−&lt;/sup&gt; (−6)</td>
<td>3.48 ± 0.27&lt;sup&gt;−&lt;/sup&gt; (−8)</td>
</tr>
<tr>
<td>Catalase&lt;sup&gt;−&lt;/sup&gt;</td>
<td>65.28 ± 4.47</td>
<td>68.47 ± 6.81&lt;sup&gt;−&lt;/sup&gt; (−5)</td>
<td>35.52 ± 2.75&lt;sup&gt;−&lt;/sup&gt; (−45)</td>
<td>56.11 ± 3.77&lt;sup&gt;−&lt;/sup&gt; (−58)</td>
</tr>
</tbody>
</table>

Values are mean ± SEM of eight rats. *p < 0.05, **p < 0.01, ***p < 0.001, NS (non-significant). PnlE-treated group was compared with respective vehicle-treated group. NIDDM control was compared with normal control. Values in parentheses represent the percent change. Units: <sup>a</sup>mg/dL; <sup>b</sup>mg/g; <sup>c</sup>U/mg protein; <sup>d</sup>nmol H<sub>2</sub>O<sub>2</sub> decomposed/s per g tissue.

---

**Figure 1.** Effect of PnlE on oral glucose tolerance test.
the SOD activity declined only marginally. Oral administration of PnlE to both IDDM and NIDDM animals significantly increased the catalase activity accompanied by a small increase in SOD activity. The activities of these enzymes in normal animals on the other hand did not register any changes upon PnlE administration.

Thus, our study shows that PnlE is both hypoglycemic and hypolipidemic in IDDM animals and predominately hypolipidemic in NIDDM animals. However, PnlE exhibited its antiperoxidative and antioxidant activities in both experimental diabetic groups. The effects of PnlE on normal animals were neither hypoglycemic nor hypolipidemic but appeared to maintain the euglycemic and eu lipidemic status of these animals. Further investigation in a dose-dependent manner is in progress.

Acknowledgments

The financial assistance in the form of a research fellowship to J.H.B. from the Puri Foundation, Gandhinagar, Gujarat, India, is gratefully acknowledged.

References


Copyright of Pharmaceutical Biology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.